In other cohorts, gynaecological cancers such as endometrial cancer or low grade ovarian cancers that overexpress ERs and PRs can respond to hormonal therapies [7, 9], and it has been noted that PR status indicates better prognosis in ovarian and endometrial cancers [10–13], although in cervical cancer the receptor status is not thought to be correlated with survival [14]. This evidence concerns the gene PGR and cervical cancer.